| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Tetratricopeptide repeat (TPR) domains of co-chaperone proteins (e.g., Hop, CHIP, Hsp70-interacting proteins).
|
|---|---|
| ln Vitro |
In vitro, Hsp70-derived octapeptide binds to TPR domains of co-chaperone proteins, disrupting the interaction between full-length Hsp70 and its TPR-containing partners. This peptide serves as a competitive inhibitor of Hsp70-co-chaperone interactions, allowing researchers to study the functional consequences of disrupting these protein-protein interactions. The peptide is derived from the highly conserved C-terminal region of Hsp70 family members.
|
| ln Vivo |
In vivo, Hsp70-derived octapeptide is used as a research tool to study the role of Hsp70-co-chaperone interactions in cellular stress responses and protein homeostasis. No specific therapeutic applications or in vivo efficacy data are reported. The peptide is not administered systemically for therapeutic purposes; it is used primarily as a probe in biochemical and cell-based assays.
|
| Enzyme Assay |
Binding assays are performed using purified TPR domain-containing proteins (e.g., Hop TPR1, TPR2 domains, or full-length co-chaperones) or using cell lysates containing these proteins. The peptide is immobilized on a solid support (e.g., biotinylated peptide bound to streptavidin beads) and incubated with protein lysates or purified proteins in binding buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM DTT, protease inhibitors) at 4degC for 2-4 hours. Bound proteins are washed and eluted, then analyzed by SDS-PAGE and Western blot using antibodies against the co-chaperone proteins. For competitive binding assays, increasing concentrations of free Hsp70-derived octapeptide (0.1-100 microM) are added to compete with immobilized peptide. Binding affinity can be measured using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC).
|
| Cell Assay |
Cells (e.g., HeLa, HEK-293, or other mammalian cell lines) are cultured in appropriate medium. For peptide delivery, cells are treated with the Hsp70-derived octapeptide (with or without cell-penetrating peptide conjugation) at concentrations of 10-100 microM for 2-24 hours. Alternatively, the peptide can be microinjected or delivered using transfection reagents. Protein-protein interactions between Hsp70 and co-chaperones are assessed by co-immunoprecipitation (Co-IP) from cell lysates: cells are lysed in IP buffer, incubated with anti-Hsp70 antibody, and precipitated with protein A/G beads. The presence of co-chaperones in the immunoprecipitate is analyzed by Western blot. Cellular stress responses (e.g., heat shock response, unfolded protein response) can be assessed by measuring downstream targets.
|
| Animal Protocol |
Hsp70-derived octapeptide is primarily used in biochemical and cell-based assays; no standardized in vivo animal models are established for this compound. For in vivo studies, the peptide may be administered to animal models via intravenous or intraperitoneal injection (with or without conjugation to cell-penetrating peptides) to study the effects of disrupting Hsp70-co-chaperone interactions on stress responses, protein aggregation, or disease models. Doses and regimens would need to be determined empirically.
|
| ADME/Pharmacokinetics |
The Hsp70-derived octapeptide has molecular formula C3₆H₅₈N₈O1₆ and molecular weight 858.89. It is soluble in water (1.82 mg/mL, 2.12 mM with ultrasonication and pH adjustment to 1 with HCl). The peptide is stored at -20degC for long-term stability. As a short peptide, it is susceptible to proteolytic degradation and may have limited stability in biological matrices.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for Hsp70-derived octapeptide. As a peptide derived from an endogenous protein, it is expected to have low toxicity. The compound is for research use only and not for human therapeutic use. Standard safety precautions for handling peptides should be observed.
|
| References |
|
| Additional Infomation |
Hsp70-derived octapeptide is a conserved peptide sequence from the C-terminal end of Hsp70 that physically interacts with tetratricopeptide repeat (TPR) motifs. It is a synthetic peptide fragment used as a research tool to study Hsp70-co-chaperone interactions and the role of the Hsp70 chaperone system in protein folding, stress responses, and disease. The peptide is not an approved therapeutic agent. It is available as a research-grade compound for laboratory use. The peptide's sequence corresponds to the conserved EEVD motif and surrounding residues at the Hsp70 C-terminus, which is critical for TPR domain binding.
|
| Molecular Formula |
C36H58N8O16
|
|---|---|
| Molecular Weight |
858.89
|
| Exact Mass |
858.397
|
| CAS # |
736171-62-3
|
| PubChem CID |
445379
|
| Appearance |
White to off-white solid powder
|
| LogP |
-5.1
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
60
|
| Complexity |
1610
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1CC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N[C@H](C(N[C@H](C(=O)N[C@H](C(=O)O)CC(O)=O)C(C)C)=O)CCC(O)=O)CCC(=O)O)=O)[C@@H](C)CC)=O)[C@H](O)C)=O)N1C(=O)CN
|
| InChi Key |
ZFLYGBZWZFFSEA-KXIJWNIYSA-N
|
| InChi Code |
InChI=1S/C36H58N8O16/c1-6-17(4)28(42-35(58)29(18(5)45)43-32(55)22-8-7-13-44(22)23(46)15-37)34(57)39-19(9-11-24(47)48)30(53)38-20(10-12-25(49)50)31(54)41-27(16(2)3)33(56)40-21(36(59)60)14-26(51)52/h16-22,27-29,45H,6-15,37H2,1-5H3,(H,38,53)(H,39,57)(H,40,56)(H,41,54)(H,42,58)(H,43,55)(H,47,48)(H,49,50)(H,51,52)(H,59,60)/t17-,18+,19-,20-,21-,22-,27-,28-,29-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~1.82 mg/mL (~2.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1643 mL | 5.8215 mL | 11.6429 mL | |
| 5 mM | 0.2329 mL | 1.1643 mL | 2.3286 mL | |
| 10 mM | 0.1164 mL | 0.5821 mL | 1.1643 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
